N-methylglucamine

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-methylglucamine
• 英文别名: (3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol
• 化学式: C₇H₁₇NO₅
• 分子量: 195.216
• InChiKey: MBBZMMPHUWSWHV-LMMQKCLSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.8
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  113
• 氢给体数：
  6
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-methylglucamine 、 5,6-dihydro-4,5-dioxo-9-methyl-4H-pyrano<3,2-c>quinoline-2-carboxylic acid 在 甲烷 作用下， 以 水 为溶剂， 以80%的产率得到N-methylglucamine salt of 5,6-dihydro-4,5-dioxo-9-methyl-4H-pyrano<3,2-c>quinoline-2-carboxylic acid
  参考文献：
  名称：

  Morinaka; Takahashi; Hata, European Journal of Medicinal Chemistry, 1981, vol. 16, # 3, p. 251 - 256

  摘要：

  DOI：

文献信息

• PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20210061798A1

  公开（公告）日：2021-03-04

  Disclosed herein are embodiments of a pyrazole compound according to formula I. Compositions comprising the compound, and a method for making the composition also are disclosed. The composition may comprise a carrier, such as a polymer and/or the composition may be a spray-dried formulation. Also disclosed is a method for using the compound and/or composition. The compound and/or composition may be useful to inhibit an IRAK protein and/or to ameliorate, treat and/or prevent an IRAK-associated disease or condition in a subject.

  披露了根据公式I的吡唑化合物的一种实施例。还披露了包含该化合物的组合物以及制造该组合物的方法。该组合物可以包含载体，例如聚合物和/或该组合物可以是喷雾干燥的制剂。还披露了一种使用该化合物和/或组合物的方法。该化合物和/或组合物可用于抑制IRAK蛋白和/或在主体上改善、治疗和/或预防IRAK相关疾病或状况。
• [EN] CAMPTOTHECIN DERIVATIVES<br/>[FR] DÉRIVÉS DE CAMPTOTHÉCINE
  申请人：IMMUNOGEN INC

  公开号：WO2020219287A1

  公开（公告）日：2020-10-29

  Disclosed herein are novel cytotoxic compounds, and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this disclosure relates to novel camptothecin derivatives thereof, intermediates thereof, conjugates thereof, and pharmaceutically acceptable salts thereof, which are useful as medicaments, in particular as anti-proliferative agents (anticancer agents).

  本文披露了新型细胞毒性化合物，以及包含这些细胞毒性化合物和细胞结合剂的细胞毒性结合物。更具体地说，本公开涉及新型紫杉醇衍生物，其中间体，结合物以及其药用可接受盐，这些化合物可作为药物使用，特别是作为抗增殖剂（抗癌剂）。
• NOVEL ANTICANCER AGENT
  申请人：Kyoto Pharmaceutical Industries, Ltd.

  公开号：EP3153508A1

  公开（公告）日：2017-04-12

  The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.

  本发明的问题是提供一种有用的萘呋喃化合物原药化合物。本发明涉及一种由式（IA）表示的化合物： [其中各符号如说明书所述]或其药学上可接受的盐。
• PEMETREXED FORMULATION
  申请人：Actavis Group PTC ehf

  公开号：EP2983649A1

  公开（公告）日：2016-02-17
• Antimicrobial Compositions with Effervescent Agents
  申请人：Melinda Therapeutics

  公开号：US20150366857A1

  公开（公告）日：2015-12-24

  The present invention relates to pharmaceutical compositions comprising a quinolone carboxylic acid derivative antimicrobial agent and an effervescent agent. These compositions have improved gastrointestinal tolerability and/or reduced potential to cause gastrointestinal side effects. These compositions are useful for oral administration, for treating, preventing, or reducing the risk of microbial infections.